TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:53
BIONOMICS LIMITED/FI ( BNOX ) https://www.bionomics.com.au
4.45USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Australia
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-76.08%
BNOX
SPY
32.66%
-97.05%
BNOX
SPY
108.59%
BNOX
0.00%
SPY
302.52%
BNOX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
69.42
61.56
0.59
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-4.12
202.08
4.07
-13.49
0.00
-6.63
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-3606.10
-5225.03
-2347.44
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-86801.68
-88520.38
0.00
Other Earnings and Cash Flow Stats:
BIONOMICS LIMITED/FI ( BNOX ) Net Income TTM ($MM) is -11.44
BIONOMICS LIMITED/FI ( BNOX ) Operating Income TTM ($MM) is -16.29
BIONOMICS LIMITED/FI ( BNOX ) Owners' Earnings Annual ($MM) is 0.00
BIONOMICS LIMITED/FI ( BNOX ) Current Price to Owners' Earnings ratio is 0.00
BIONOMICS LIMITED/FI ( BNOX ) EBITDA TTM ($MM) is -14.92
BIONOMICS LIMITED/FI ( BNOX ) EBITDA Margin is -2347.44%
Capital Allocation:
BIONOMICS LIMITED/FI ( BNOX ) has paid 0.00 dividends per share and bought back 1865.958718 million shares in the past 12 months
BIONOMICS LIMITED/FI ( BNOX ) has increased its debt by 0.21935 million USD in the last 12 months
Capital Structure:
BIONOMICS LIMITED/FI ( BNOX ) Interest-bearing Debt ($MM) as of last quarter is 0
BIONOMICS LIMITED/FI ( BNOX ) Annual Working Capital Investments ($MM) are 1
BIONOMICS LIMITED/FI ( BNOX ) Book Value ($MM) as of last quarter is 17
BIONOMICS LIMITED/FI ( BNOX ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
BIONOMICS LIMITED/FI ( BNOX ) has 8 million in cash on hand as of last quarter
BIONOMICS LIMITED/FI ( BNOX ) has 2 million of liabilities due within 12 months, and long term debt 0 as of last quarter
BIONOMICS LIMITED/FI ( BNOX ) has 15 common shares outstanding as of last quarter
BIONOMICS LIMITED/FI ( BNOX ) has 0 million USD of preferred stock value
Academic Scores:
BIONOMICS LIMITED/FI ( BNOX ) Altman Z-Score is -4.98 as of last quarter
BIONOMICS LIMITED/FI ( BNOX ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
BIONOMICS LIMITED/FI ( BNOX ) largest shareholder is Bvf Inc owning 47372 shares at 0.21 ($MM) value
(an insider) shares of BIONOMICS LIMITED/FI ( BNOX ) for the amount of $ on
33.91% of BIONOMICS LIMITED/FI ( BNOX ) is held by insiders, and 16.22% is held by institutions
BIONOMICS LIMITED/FI ( BNOX ) went public on 2021-12-16
Other BIONOMICS LIMITED/FI ( BNOX ) financial metrics:
FCF:-10.24
Unlevered Free Cash Flow:0.00
EPS:-0.02
Operating Margin:-3606.10
Gross Profit Margin:-5225.03
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-18.86
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About BIONOMICS LIMITED/FI ( BNOX ) :
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.